DUBLIN--(BUSINESS WIRE)--The "Melanoma Therapeutics Market Analysis by Therapy, by Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generics) and Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.
The global melanoma therapeutics market is expected to reach USD 12.4 billion by 2025. Increasing incidence of chronic diseases such as melanoma, skin cancer, and skin allergies is an important driver of the market.
Increasing number of FDA approvals and introduction of novel therapeutics with enhanced efficacy are also anticipated to present growth opportunities. Within a period of 6 years, i.e., from 2011 to 2016, around eight biologics have been approved for the treatment of this disease, which include Opdivo, Yervoy, Cotellic, Zelboraf, Keytruda, Mekinist, Tafinlar, and Imlygic.
Companies are undertaking various R&D activities to find new indications for existing products and development of innovative molecules. For instance, in September 2014, the U.S. FDA approved patented drug Keytruda (Merck & Co., Inc.) to treat metastatic melanoma, thereby extending the therapeutic application of its product. This drug was initially approved for treatment of non-small cell lung cancer.
Furthermore, many pharmaceutical companies in the U.S., Europe, and Asia Pacific are focusing on development of new biologics. For instance, in March 2017, Daiichi Sankyo Company, Limited announced a collaborative drug discovery project Take a New challenge for Drug discovery (TaNeDS) to facilitate new drug development through collaborations.
Key Topics Covered:
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Melanoma Therapeutics Market Variables, Trends & Scope
Chapter 4 Melanoma Therapeutics Market: Therapy Estimates & Trend Analysis
Chapter 5 Melanoma Therapeutics Market: Drug Estimates & Trend Analysis
Chapter 6 Melanoma Therapeutics Market: Regional Estimates & Trend Analysis, by Therapy, and Drug
Chapter 7 Competitive Landscape
- AB Sciences
- Amgen, Inc.
- AstraZeneca
- Bristol-Myers Squibb Company
- Company Profiles
- Daiichi Sankyo Company, Limited
- F. Hoffman-La Roche Ltd.
- Market Participation
- Merck & Co., Inc.
- Novartis AG
- Strategy Framework
For more information about this report visit https://www.researchandmarkets.com/research/db8d4v/melanoma
